Physician profile
Sofia Yaseen Arain
NPI 1831129741
$1,804.02
in general payments reported to CMS, 2019-2025
15 companies · $353 in 2025
The $353 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.20 · 2020: $18.35 · 2021: $46.46 · 2022: $108 · 2023: $639 · 2024: $557 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $466.83 | 2019-2023 | Bexsero |
| Sanofi-Aventis U.S. LLC | $326.81 | 2024-2025 | |
| Rhythm Pharmaceuticals, INC. | $125.54 | 2023 | Imcivree |
| Ars Pharmaceuticals Operations, INC. | $125.00 | 2025 | Neffy |
| Pfizer INC. | $119.49 | 2019-2025 | |
| Cranial Technologies, INC | $108.83 | 2024-2025 | Doc Band |
| Phadia US INC. | $103.45 | 2021-2024 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $95.02 | 2025 | Zoryve |
| Sanofi Pasteur INC. | $93.22 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $83.07 | 2019-2023 | Vaxneuvance, Gardasil 9 |
| Cumberland Pharmaceuticals, INC. | $56.10 | 2023-2024 | Kristalose |
| Boston Scientific Corporation | $33.56 | 2022 | |
| Kaleo, INC. | $32.77 | 2023 | Auvi-Q |
| Seqirus USA INC | $17.72 | 2024 | Flucelvax |
| Verrica Pharmaceuticals INC. | $16.61 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Arain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.